🏛️ Verified NIH Record • Updated 2026-05-01

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy (NCT01829958)

🔵 Active, Not Recruiting Observational / Diagnostic 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (22 items) and avoid the listed exclusions (10 items).

Location: Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Subjects meeting the following criteria will be excluded from enrollment in the study:
  • Enrollment in a Phase I trial
  • Previously enrollment in this study
  • Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm.
  • Contraindication to use of rituximab or prednisone including:
  • Uncontrolled diabetes mellitus
  • Systemic fungal infection
  • Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis) will be excluded. Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines and may be included in the study.
  • History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions ≤ Grade 3.
  • Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (8 Sites)

  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen — Montvale, New Jersey
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Memorial Sloan Kettering Rockville Centre — Rockville Centre, New York
  • Memorial Sloan Kettering Nassau — Uniondale, New York

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗